Assenagon Asset Management S.A. Trims Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Assenagon Asset Management S.A. cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 18.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 255,602 shares of the medical research company's stock after selling 58,663 shares during the quarter. Assenagon Asset Management S.A. owned 0.14% of IQVIA worth $50,228,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Private Trust Co. NA raised its holdings in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after purchasing an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC grew its position in IQVIA by 1.3% during the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company's stock worth $941,000 after buying an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its position in IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after purchasing an additional 50 shares during the period. Fortitude Family Office LLC lifted its holdings in shares of IQVIA by 2.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company's stock worth $468,000 after acquiring an additional 56 shares during the period. Finally, Huntington National Bank boosted its holdings in IQVIA by 7.4% during the third quarter. Huntington National Bank now owns 809 shares of the medical research company's stock valued at $192,000 after purchasing an additional 56 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on IQV shares. BTIG Research decreased their price objective on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. The Goldman Sachs Group cut their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Evercore ISI dropped their price target on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $255.82.

IQVIA Price Performance

Shares of NYSE:IQV traded up $1.61 during mid-day trading on Thursday, reaching $197.71. The stock had a trading volume of 1,208,107 shares, compared to its average volume of 1,297,661. The company has a market cap of $35.89 billion, a P/E ratio of 25.95, a price-to-earnings-growth ratio of 2.09 and a beta of 1.48. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The business's 50 day moving average price is $200.93 and its 200 day moving average price is $221.44. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.